Enliven Therapeutics, Inc. (ELVN) – What Are Analysts Saying About This Stock?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $74.44.

Several equities analysts recently issued reports on ELVN shares. Guggenheim reissued a “buy” rating on shares of Enliven Therapeutics in a report on Thursday. William Blair started coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating for the company. Morgan Stanley began coverage on Enliven Therapeutics in a report on Friday, October 2nd. They set an “overweight” rating and a $70.00 target price for the company. Barclays started coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 target price for the company. Finally, Stifel Nicolaus upped their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, August 6th.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $50.35, for a total value of $303,006.30. Following the sale, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at $1,913,300. This represents a 13.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the completion of the sale, the director owned 13,000 shares in the company, valued at $606,710. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 189,849 shares of company stock worth $11,140,085. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. KBC Group NV purchased a new stake in shares of Enliven Therapeutics in the first quarter worth about $38,000. State of Wyoming purchased a new position in Enliven Therapeutics during the second quarter valued at approximately $96,000. FNY Investment Advisers LLC purchased a new position in Enliven Therapeutics during the second quarter valued at approximately $126,000. Arizona State Retirement System lifted its holdings in Enliven Therapeutics by 45.1% in the second quarter. Arizona State Retirement System now owns 13,007 shares of the company’s stock valued at $660,000 after acquiring an additional 4,042 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in Enliven Therapeutics by 21.2% in the first quarter. The Manufacturers Life Insurance Company now owns 23,441 shares of the company’s stock valued at $919,000 after acquiring an additional 4,105 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Stock Up 0.9%

Shares of Enliven Therapeutics stock opened at $40.98 on Friday. The stock’s fifty day moving average is $54.08 and its two-hundred day moving average is $47.73. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32. The company has a market capitalization of $3.00 billion, a PE ratio of -24.54 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, research analysts anticipate that Enliven Therapeutics will post -1.75 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.